NCT02730793 is a Phase 2 clinical trial of Oral Aztreonam in Cystic Fibrosis, sponsored by Virginia Commonwealth University.

Who is sponsoring NCT02730793?

NCT02730793 is sponsored by Virginia Commonwealth University.

What drugs are being tested in NCT02730793?

Interventions in NCT02730793: Oral Aztreonam, Nasal Aztreonam, Nasal Placebo.

What condition does NCT02730793 study?

NCT02730793 studies Cystic Fibrosis.

Is NCT02730793 still recruiting?

NCT02730793 is currently terminated. Last updated 11 January 2021.

Are results published for NCT02730793?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-01-11 · How we verify

NCT02730793

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

Terminated Phase 2 Results posted Last updated 11 January 2021

What this trial tests

Phase 2 trial testing Oral Aztreonam in Cystic Fibrosis in 5 participants. Terminated before completion.

Timeline

1 January 2017

Primary endpoint
19 September 2019

19 September 2019

Quick facts

Lead sponsor	Virginia Commonwealth University
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	5
Start date	1 January 2017
Primary completion	19 September 2019
Estimated completion	19 September 2019
Sites	1 location across United States

Drugs / interventions tested

Oral Aztreonam — full drug profile →
Nasal Aztreonam — full drug profile →
Nasal Placebo

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Virginia Commonwealth University

Who can join

Adults 7 to 100, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Protocol-defined Pulmonary Exacerbations Treated With IV Anti-pseudomonal Antibiotics on Day 140
Time frame: 140 days
Protocol-Defined Pulmonary Exacerbation includes events that are characterized by change or worsening pulmonary symptoms (increased cough, increased sputum production and chest congestion, decreased appetite and exercise tolerance), loss of weight, and lung function decline that prompt initation of antibiotic therapy. Protocol-defined exacerbations in subjects that warrant treatment with IV antibi

Sponsor's own description

This study is designed as a masked, two center, randomized, placebo-controlled pilot study to evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth University Medical Center (VCU) and Eastern Virginia Medical School (EVMS). Potential subjects will be identified in each site's CF clinic.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.
Smith S, Rowbotham NJ. · · 2022 · cited 18× · PMID 36373968 · DOI 10.1002/14651858.cd001021.pub4

Verify or expand the search:

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Other Virginia Commonwealth University trials

Trials by the same sponsor.

NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02730793 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
Last refreshed: 11 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02730793.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing